Autonomix Medical, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Autonomix Medical, Inc. is a medical device company specializing in the development and commercialization of precision nerve-targeted therapies to transform the treatment of peripheral nervous system diseases. The company’s core products include a proprietary platform that utilizes precision guidance technology combining nerve sensing and radio frequency (RF) ablation to sense, treat, and verify nerve signaling through a minimally invasive, transvascular procedure. This platform initially targets severe pain associated with pancreatic cancer and aims to provide rapid, effective, and durable pain relief while enabling significant opioid reduction in patients. Autonomix leverages this first-in-class platform technology across multiple potential therapeutic areas including chronic pain management, hypertension, cardiology, pulmonology, and gastroenterology. The company’s technology is protected by an extensive intellectual property portfolio encompassing over 120 issued or pending patents globally. Founded in 2009 and headquartered in The Woodlands, Texas, Autonomix operates primarily in the United States while advancing global clinical development. Recent major developments include successful progression through a first-in-human proof-of-concept clinical study that demonstrated sustained, clinically meaningful improvements in quality of life and pain reduction for pancreatic cancer patients. This study underpins the company’s planned multicenter pivotal clinical trial in the U.S. set to begin in 2026, supporting its regulatory pathway toward a De Novo FDA classification expected by 2027. Autonomix also commenced a Good Laboratory Practice (GLP) preclinical study for its combined sensing and ablation system and has raised over $15 million through private placements and public offerings during 2024 and 2025 to fund ongoing clinical and regulatory activities. The company is expanding its pipeline beyond pancreatic cancer, exploring applications in cardiovascular, pulmonary, and chronic pain indications. Autonomix maintains active clinical site agreements and strategic partnerships to support its clinical trial execution and is highlighted frequently in scientific conferences to showcase its innovative technology and clinical progress.
Company News
Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026
Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery
Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules
Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission
Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award
Autonomix Stock Skyrockets After Obtaining Key Cancer Tech Patent
Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy
Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study
Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study
Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform
Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform
Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
Autonomix Medical wins new patent for neural sensing technology
Autonomix Medical wins new patent for neural sensing technology
Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant
Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant
Autonomix Medical Announces Standalone Neural Sensing Program with Evidence of Real-Time Renal Nerve Activity Change
Autonomix Announces Reverse Stock Split
Autonomix Announces Reverse Stock Split